CD19 and diffuse large B-cell lymphoma: LT targets CD19-expressing cells with a potent cytotoxin, while roflumilast inhibits PDE4, which is overexpressed in the non-germinal center B-cell-like (GCB) subtype and linked to poor prognosis, to disrupt key survival pathways in DLBCL, together impairing tumor cell growth and survival.